ARTICLE | Regulation

AMNOG's uncharted waters

How AMNOG pricing may work for mixed-benefit drugs in Germany

January 30, 2012 8:00 AM UTC

The authors of AMNOG, Germany's new drug pricing law, evidently didn't consider what to do when a drug shows benefit in some patient subgroups but not in others. These drugs, which are rapidly becoming the norm, don't fit into either of the scheme's two categories: premium priced or reference priced.

Hints about how Germany will handle the pricing of so-called mixed-benefit drugs could come in the next six months, when AstraZeneca plc wraps up its pricing negotiations for Brilique ticagrelor to prevent atherothrombotic events in acute coronary syndrome (ACS) patients...